Ex Parte Short - Page 12



          Interference No. 105,188                                                    
          Short v. Punnonnen                                                          
                    According to one embodiment, plasmid DNA is introduced            
               into a simian COS cell line . . . by known methods of                  
               transfection . . . and allowed to replicate and express cDNA           
               inserts.  The transfectants expressing B7-1 antigen are                
   5           depleted with an anti-B7-1 monoclonal antibody . . . and               
               anti-murine IgG and IgM coated immunomagnetic beads.                   
               Transfectants expressing human B7-2 antigen can be                     
               positively selected by reacting the transfectants with the             
               fusion proteins CTLA4Ig and CD28Ig, followed by panning with           
  10           anti-human Ig antibody coated plates.  Although human                  
               CTLA4Ig and CD28Ig fusion protiens were used in the examples           
               described herein, given the cross-species reactivity between           
               B7-1 and, for example murine B7-1, it can be expected that             
               other fusion proteins reactive with another cross-reactive             
  15           species could be used.  After panning, episomal DNA is                 
               recovered from the panned cells and transformed into a                 
               competent bacterial host . . . .  Plasmid DNA is                       
               subsequently reintroduced into COS cells and the cycle of              
               expression and panning repeated at least two times.  After             
  20           the final cycle, plasmid DNA is prepared from individual               
               colonies, transfected into COS cells and analyzed for                  
               expression of novel B lymphocyte antigens by indirect                  
               immunofluorescence with, for example, CTLA4Ig and CD28Ig.              
  25      Example 4 (Exh. 2040, B. Cloning Procedure, p. 72, ll. 6-32) and            
          Example 6 (Exh. 2040, B. Cloning Procedure, p. 80, ll. 8-34)                
          explain how the recursive screening steps of the procedures                 
          described in the Freeman PCT select polynucleotide sequences                
          which encode novel human or murine B7-2 variants having markedly            
  30      enhanced or inhibited immune responses to a vaccine vector.                 
               Focusing on the detailed teachings of the Freeman PCT, we              
          find that one method described in this primary reference for                
          obtaining an immunomodulatory polynucleotide that encodes a B7-2            
          antigen which has an altered modulatory effect on an immune                 
  35      response induced by a genetic vaccine vector as compared to the             
                                        -12-                                          




Page:  Previous  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  Next 

Last modified: November 3, 2007